Cannabidiol, a plant-derived compound, is an emerging strategy for treating cognitive impairments: comprehensive review of randomized trials.

Adriana Yndart Arias, Kamila Vadell, Arti Vashist, Nagesh Kolishetti, Madepalli K. Lakshmana, Madhavan Nair +1 more

Background Finding new strategies to treat cognitive disorders is a challenging task. Medication must defeat the blood-brain barrier. Cannabidiol (CBD), a non-intoxicating compound of the cannabis plant, has gained recognition as a nutraceutical for its potential effectiveness in treating anxiety, oxidative stress, convulsions, and inflammation. However, the dose, tolerable upper intake, formulation, administratio…

Determination of Prenatal Substance Exposure Using Meconium and Orbitrap Mass Spectrometry.

Atakan Hernandez, Valerie Lacroze, Natalia Doudka, Jenny Becam, Carole Pourriere-Fabiani, Bruno Lacarelle +4 more

The aim of this study was to develop and to validate a toxicological untargeted screening relying on LC-HRMS in meconium including the detection of the four main classes of drugs of abuse (DoA; amphetamines, cannabinoids, opioids and cocaine). The method was then applied to 29 real samples. Analyses were performed with a liquid chromatography system coupled to a benchtop Orbitrap operating in a data-dependent anal…

Methamphetamine Blocks Adenosine A2A Receptor Activation via Sigma 1 and Cannabinoid CB1 Receptors.

Mireia Casanovas, Irene Reyes-Resina, Alejandro Lillo, Jaume Lillo, Raul López-Arnau, Jorge Camarasa +4 more

Methamphetamine is, worldwide, one of the most consumed drugs of abuse. One important side effect is neurodegeneration leading to a decrease in life expectancy. The aim of this paper was to check whether the drug affects one of the receptors involved in neurodegeneration/neuroprotection events, namely the adenosine A2A receptor (A2AR). First, we noticed that methamphetamine does not affect A2A functionality if the…

THC for age-related cognitive decline?

Yosef Sarne